News
The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...
A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...
Catalent is laying off 350 employees in its gene therapy manufacturing division in Baltimore “due to an unexpected shift in ...
As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...
Alembic, Sun and Glenmark issue US drug recalls due to the presence of carcinogens or foreign matter
A trio of Indian drugmakers—Alembic Pharmaceuticals, Sun Pharmaceutical and Glenmark Pharmaceuticals—issued separate ...
With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...
After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...
With sales of atopic dermatitis (AD) treatment Adbry scaling up in the U.S., Leo Pharma is accomplishing one of the goals established by CEO Christophe Bourdon when he took over at the Danish ...
Pigot most recently served as chief commercial officer at Aerovate Therapeutics, which was developing a dry powder inhaled ...
The company’s Aspirina pain relief pills are now available for purchase in select Walmart and Walgreens stores in the U.S.
Amgen laid out $3.7 billion to get its hands on ChemoCentryx and its approved drug Tavneos in August of 2022. At the time, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results